Narrowing the Gap. Clinical Development and Regulatory Pathways for Medical Technologies for Neglected Diseases. Tom Bollyky
|
|
- Adela Simmons
- 8 years ago
- Views:
Transcription
1 Narrowing the Gap Clinical Development and Regulatory Pathways for Medical Technologies for Neglected Diseases Tom Bollyky Stanford Law School Drug Development and International Access Conference April 9, 2010
2 Overview Disclaimer Health Product Development for Neglected Diseases Tremendous Recent Progress; Looming Challenges Potential Funding Gap The Clinical Development Pathway for Medical Technologies for Neglected Diseases Moving towards a Sustainable Strategy for Bringing Clinical Trial Costs and Finances into Better Balance SLS - 2 4/9/10
3 Neglected Diseases Disclaimer Chronic infectious diseases that affect rural and urban poor in low and middle-income countries 1 billion people, including 400 million children, suffer from one or more neglected tropical diseases (NTDs). If HIV/AIDS, Malaria, and TB included, affected population is much larger. Millions of deaths per year, many more disabled or deformed, undermines economic development, education, and security. SLS - 3 4/9/10
4 Historically, Few Products for NDs Disclaimer Many NTDs have no viable treatment or prevention options The 10/90 gap only 10% of worldwide expenditure on health research and development has been devoted to the problems that primarily affect 90% of the world's population. Of the 1393 new chemical entities approved between 1975 and 1999, only 46 (3.3%) were for neglected diseases (including HIV/AIDS, Malaria, and TB). SLS - 4 4/9/10
5 Increased Recent Attention and Funding Disclaimer Between 1999 and 2009, annual funding for neglected diseases rose 25-fold ($2.5 billion in 2007) 60% of the total spending on neglected diseases was from the Bill and Melinda Gates Foundation and U.S. National Institutes of Health Biopharmaceutical industry provided 9% of the total spending plus in-kind contributions of expertise and services 80% of the funding has gone to HIV/AIDS, Malaria, and TB SLS - 5 4/9/10
6 Push Disclaimer and Pull Mechanisms Efforts to create incentives for health product discovery, development, and delivery for neglected diseases can be divided into two general categories Push mechanisms -- subsidize or lower costs of R&D Grants, tax credits, and subsidies Expedited regulatory review Liability Protection Pull mechanisms increase potential reward for successful R&D and delivery Advance market commitments Prizes Intellectual Property and market exclusivity incentives Priority Review Vouchers Most funding to date has been push self-funded research or to Public-Private Product Development Partnerships (PDPs) and other intermediaries SLS - 6 4/9/10
7 Tremendous Progress; Looming Challenges Disclaimer Tremendous progress over the last decade in building the pipeline for health products for neglected diseases Led by efforts of PDPs, dozens of products in now pipeline Challenges loom: potential shortfall in financing for clinical development limited research and regulatory capacity for late stage trials SLS - 7 4/9/10
8 Challenges of Clinical Development Generally Disclaimer Clinical trials for drugs and vaccines have become increasingly time consuming and expensive Clinical development can be as much as 70% of the total cost of developing a medical technology Process can last between years Success rates low SLS - 8 4/9/10
9 SLS - 9 4/9/10
10 Challenges of the Clinical Development of Products Disclaimer for Neglected Diseases Trials must occur in disease-endemic countries, which often have limited clinical research capacity and regulatory infrastructure Difficult regulatory and ethical challenges posed by the study products and subjects Trials are often large-scale, multi-center, and multicountry SLS /9/10
11 SLS /9/10
12 SLS /9/10
13 Challenges of the Clinical Development of Products Disclaimer for Neglected Diseases Trials must occur in disease-endemic countries, which often have limited clinical research capacity and regulatory infrastructure Difficult regulatory and ethical challenges posed by the study products and subjects Trials are often large-scale, multi-center, and multicountry SLS /9/10
14 SLS /9/10
15 SLS /31/10
16 Challenges of the Clinical Development of Products Disclaimer for Neglected Diseases Trials must occur in disease-endemic countries, which often have limited clinical research capacity and regulatory infrastructure Difficult regulatory and ethical challenges posed by the study products (often vaccines) and subjects (frequently pediatric, in devastatingly poor settings) Trials are often large-scale, multi-center, and multicountry SLS /9/10
17 Basic Elements of the Clinical Trial Process Pre-Trial Establish working group to develop idea Estimate costs & obtain financing Develop trial protocol, patient information sheet, consent form Record trial on an international clinical trials register Trial Set -Up Protocol authorization from regulatory authority Obtain ethical approval from Institutional Review Board (IRB) Implement procedures for drug handling Develop the case report forms Negotiate the necessary agreements and contacts Obtain approval from each site Set up site assessment & initiation Activate sites During Trial End of Trial Conduct trial; monitor progress in sites Independent Data Monitoring Committee Send annual safety report to regulatory authority Send Annual Progress & Safety report to Ethics Committee Lock database & Close trial (inform regulatory authority) Published first efficacy and safety results Long-term follow up (efficacy and/or safety)
18 PATH/GSK Disclaimer RTS,S Phase III Trial 11 clinical trial sites 7 countries 40 IRBs 16,000 children and infants SLS /9/10
19 A Sustainable Strategy for Bringing Clinical Trial Disclaimer Costs and Finances into Better Balance Increased or innovative financing important, but reducing clinical trial cost and risks must be part of the solution Improvement in clinical development pathway necessary for increased private investment and scientific rigor, quality of trial data, and protection of subjects SLS /9/10
20 Sensible Clinical Trial Research to Neglected Disclaimer Disease Pipeline Emerging research on sensible approaches to reducing cost and risks of large scale, randomized, commercial clinical trials Potential application to products or settings most relevant for neglected diseases Vehicles for assembling and encouraging adoption of sensible clinical trial guidelines SLS /9/10
21 Regional Disclaimer Regulatory Streamlining Regional pathways with integrated regulatory and ethics reviews could have significant benefits here: Pool regional regulatory resources and share expertise Reduce unnecessary costs, delays, and risk Link to existing networks or regional economic or public health entities Potentially generate private sector funding or cross subsidies SLS /9/10
22 Thank you SLS /9/10
Bridging the Gap: Improving Clinical Development and the Regulatory Pathways for Health Products for Neglected Diseases
Bridging the Gap: Improving Clinical Development and the Regulatory Pathways for Health Products for Neglected Diseases Thomas J. Bollyky Abstract There has been tremendous progress over the last decade
More informationPROPOSAL by Bangladesh, Barbados, Bolivia and Suriname. Chagas Disease Prize Fund for the Development of New Treatments, Diagnostics and Vaccines
PROPOSAL by Bangladesh, Barbados, Bolivia and Suriname Chagas Disease Prize Fund for the Development of New Treatments, Diagnostics and Vaccines Executive Summary Date: 09.04.15 In resolution WHA 61.21,
More informationInstitute for OneWorld Health
Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The
More informationTHE 3P PROJECT. An overview of the 3P proposal to accelerate innovation and access for new treatment regimens for TB
3 rd February 2014 THE 3P PROJECT An overview of the 3P proposal to accelerate innovation and access for new treatment regimens for TB WHY THE 3P PROJECT FOR TUBERCULOSIS IS NEEDED Tuberculosis (TB) mainly
More informationProduct Development Partnerships (PDPs): Lessons from PDPs established to develop new health technologies for neglected diseases.
Product Development Partnerships (PDPs): Lessons from PDPs established to develop new health technologies for neglected diseases Cheri Grace June 2 2010 1 Executive Summary There has been little historic
More informationFederal Ministry of Education and Research
Federal Ministry of Education and Research Announcement Regulations for funding of products for the prevention, diagnosis and treatment of neglected and poverty-related diseases 1 Funding purpose Poor
More informationPROPOSAL by Bangladesh, Barbados Bolivia, and Suriname. Prize Fund for Development of Low-Cost Rapid Diagnostic Test for Tuberculosis. Date: 09.04.
PROPOSAL by Bangladesh, Barbados Bolivia, and Suriname Prize Fund for Development of Low-Cost Rapid Diagnostic Test for Tuberculosis Executive Summary Date: 09.04.15 The governments of Bangladesh, Barbados,
More informationNovartis extends commitment to help achieve final elimination of leprosy
Novartis India Limited Sandoz House Shivsagar Estate Dr Annie Besant Road Worli, Mumbai 400 018 India MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE Novartis extends commitment to help achieve final elimination
More informationIntellectual property rights, innovation and public health: prospective WIPO inputs. Preliminary briefing to WHO Commission 5 April 2004
Intellectual property rights, innovation and public health: prospective WIPO inputs Preliminary briefing to WHO Commission 5 April 2004 Two key opportunities... Public interest management of knowledge
More informationGuidelines for applicants
Funding for the development of products for the prevention, diagnosis and treatment of neglected and poverty related diseases 19 October 2015 Guidelines for applicants Please structure your application
More informationDEVELOPING WORLD HEALTH PARTNERSHIPS DIRECTORY
DEVELOPING WORLD HEALTH PARTNERSHIPS DIRECTORY OVER 250 HEALTH PARTNERSHIPS THAT MAKE A DIFFERENCE TO PEOPLE S LIVES The global health community needs to overcome both new and current challenges in the
More informationChallenges and Barriers to Efficient Operation of Existing Supply Chain
Challenges and Barriers to Efficient Operation of Existing Supply Chain Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB July 31, 2012 Professor Rifat
More informationHealth Care Challenges for the 21 st Century
Health Care Challenges for the 21 st Century Between 1992 and 2002, overall health care spending rose from $827 billion to about $1.6 trillion; it is projected to nearly double to $3.1 trillion in the
More informationProduct Development Partnerships (PDPs): Overview
Product Development Partnerships (PDPs): Overview Product Development Boot Camp 6 November 2015 Dr. Ryan Wiley President Shift Health is a healthcare strategy consultancy devoted exclusively to healthcare
More informationDNDi PROCUREMENT POLICY 2.4
DNDi PROCUREMENT POLICY 2.4 February 2014 Table of Contents 1) Why a procurement policy and how does it fit into DNDi s mission and model?... 1 2) Procurement principles... 2 3) DNDi Procurement main procedures...
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationClinical Trials: The Crux of Cancer Innovation
Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded
More informationCLINICAL DEVELOPMENT OPTIMIZATION
PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP
More informationTACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES
TRANSATLANTIC CONSUMER DIALOGUE WASHINGTON MEETING, 10-12 FEBRUARY 2000 TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES The Commission Services
More informationNational Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
More informationVoters Health Care Platform
Voters Health Care Platform This Voters Health Care Platform is based on five years of research and dialog with thousands of Americans across the country. It draws on the ideas and wishes of Americans
More informationWhy Accept Medicaid Dollars: The Facts
Why Accept Medicaid Dollars: The Facts If we accept federal Medicaid dollars, nearly 500,000 North Carolinians will gain access to health insurance. As many as 1,100 medically unnecessary deaths per year
More informationFOR NEGLECTED DISEASES
DEVELOPING NEW DRUGS & VACCINES FOR NEGLECTED DISEASES OF THE POOR The Product Developer Landscape March 2012 DEVELOPING NEW DRUGS & VACCINES FOR NEGLECTED DISEASES OF THE POOR The Product Developer Landscape
More informationIntroduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)
Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationTransforming relationships Unleashing innovation
Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationTAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
More informationPromoting innovation and improving access
NATIONAL ASSESSMENT TOOL TO ASSIST MEMBER STATES IN IMPLEMENTING THE GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY Promoting innovation and improving access
More informationBusiness plan 2015-2023. A dynamic portfolio approach to address neglected patients needs
Business plan 2015-2023 A dynamic portfolio approach to address neglected patients needs The R&D landscape for neglected but large gaps remain Review of the Business Plan to ensure impact for patients
More informationIssues paper: The EU role in global health Comments from the Institute for Global Health, University College London 9 December 2009
Issues paper: The EU role in global health Comments from the Institute for Global Health, 9 December 2009 IGH is submitting answers to 14 of the questions posed in the consultation document. Question 3:
More informationTuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationThe Global Economic Cost of Cancer
The Global Economic Cost of Cancer About the Global Economic Cost of Cancer Report Cancer is taking an enormous human toll around the world and is a growing threat in low- to middle-income countries.
More informationMarlene Haffner, MD; MPH
Marlene Haffner, MD; MPH Drug Programs for Rare Diseases: Is Right now the time for India? Marlene E. Haffner MD, MPH, CEO Haffner Associates, LLC Rare Diseases and Orphan Drug Development Initiatives
More informationStatement of revenues/expenditures and changes in fund balance. Balance sheet. Current financial liabilities. Current financial assets.
More information
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationHealth, history and hard choices: Funding dilemmas in a fast-changing world
Health, history and hard choices: Funding dilemmas in a fast-changing world Thomson Prentice Global Health Histories Health and Philanthropy: Leveraging change University of Indiana, August 2006 An embarrassment
More informationChild Care Regulations in Colorado
Child Care Regulations in Colorado Overview A summary of child care regulations in Colorado. Types of care that must be licensed Types of care that may operate without a license Age-group definitions Subsidized
More informationUC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review Cindy Gates IRB Administration Tips for Reviewer s Comments - Comments should be easily transferrable
More informationThe Coalition s Policy to Protect and Streamline Health and Medical Research Funding
1 Our Plan Real Solutions for all Australians The direction, values and policy priorities of the next Coalition Government. The Coalition s Policy to Protect and Streamline Health and Medical Research
More informationWHO Medicines Strategy. Countries at the core 2004 2007. World Health Organization
WHO Medicines Strategy Countries at the core 2004 2007 World Health Organization Expanding access to essential medicines Scaling up access to essential medicines especially for HIV/AIDS, tuberculosis and
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationSADC PHARMACEUTICAL PROGRAMME SADC PHARMACEUTICAL BUSINESS PLAN 2007-2013
SADC PHARMACEUTICAL PROGRAMME SADC PHARMACEUTICAL BUSINESS PLAN 2007-2013 SADC SECRETARIAT 27 TH JUNE 2007 ACRONYMS AIDS : Acquired Immunodeficiency Syndrome Antiretroviral ARV : Antiretroviral cgmp :
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationExpanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
More informationGLOBAL ACCESS LICENSING FRAMEWORK
GLOBAL ACCESS LICENSING FRAMEWORK Every university-developed technology with potential for further development into a drug, vaccine, or medical diagnostic should be licensed with a concrete and transparent
More informationComments on the 21 st Century Cures: Digital Health Care
Comments on the 21 st Century Cures: Digital Health Care July 22, 2014 The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide input to the House Energy
More informationPROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE
PROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE Joint study by the WHO, WIPO and WTO Secretariats Outline and overview The WHO, WIPO and the
More informationThe Prize Fund for HIV/AIDS
The Prize Fund for HIV/AIDS A New Paradigm for Supporting Sustainable Innovation and Access to New Drugs for AIDS: De-Linking Markets for Products from Markets for Innovation May 26, 2011 Introduction
More informationClinical Trials - Funding Africa's Best Practice
The European & Developing Countries Clinical Trials Partnership () 23.07.2015 Dr. Claudia Schacht & Julia Buech Eurice GmbH Content 1. overview: a) Background and Mission b) Scope 2. Project types and
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationTABLE OF COMMITMENTS
Reaching Goals On, a range of public and private partners are announcing a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by in support
More informationHow To Use Big Data In The Drug Development Process
In Focus: The role of big data in the drug development process 15-08-2014 As big data plays an increasing role in drug development and clinical trials, The Pharma Letter s Bethany Rutter spoke to Richard
More informationWhen treating a disease is bad business: orphan and neglected diseases
When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the
More informationFOREWORD. Member States in 2014 places patients and communities at the heart of the response. Here is an introduction to the End TB Strategy.
FOREWORD We stand at a crossroads as the United Nations move from the 2015 Millennium Development Goals (MDGs) to the Sustainable Development Goals (SDGs) for 2030. Integral to this transition, the world
More informationPresidential Commission for the Study of Bioethical Issues August 30, 2011 Roger I. Glass, M.D., Ph.D.
Presidential Commission for the Study of Bioethical Issues August 30, 2011 Roger I. Glass, M.D., Ph.D. NIH Associate Director, International Research Director, Fogarty International Center The Fogarty
More informationNurse Researcher or Clinical Research Nurse: Understanding the Difference
Nurse Researcher or Clinical Research Nurse: Understanding the Difference Claudia D. Smith, PhD, RN, NE-BC Director, Nursing Research St. Luke s Medical Center An Alternate Title for the Presentation:
More informationOver the last two decades, globalization of clinical trials,
, Global Clinical Trials: Ethics, Harmonization and Commitments to Transparency ; ; Carmen E. Aldinger PhD, MPH; and. All affiliated with Harvard Univeristy Over the last two decades, globalization of
More informationTranslating System Thinking for Health Systems Strengthening and Development. 1. The journey from real world practice to systems thinking
Translating System Thinking for Health Systems Strengthening and Development 1. The journey from real world practice to systems thinking Marcel Tanner & Don de Savigny Swiss Tropical & Public Health Institute
More informationCLINICAL TRIAL LIABILITY INSURANCE
CLINICAL TRIAL LIABILITY INSURANCE - R.Qaiser, Faculty Member, NIA, Pune With the opening of insurance sector and the demise of tariff regime, suddenly the Competition has become very fierce and we are
More informationINSURANCE & RISK MANAGEMENT
INSURANCE & RISK MANAGEMENT For Global Human Clinical Trials By Daniel Brettler Senior Vice President, Conner Strong & Buckelew I. GENERAL OVERVIEW Often overlooked in the early planning of a human clinical
More informationPEDIATRIC MEDICINES: GLOBAL MARKETS
PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationTsukuba Communiqué. G7 Science and Technology Ministers Meeting in Tsukuba, Ibaraki 15-17 May 2016
Tsukuba Communiqué G7 Science and Technology Ministers Meeting in Tsukuba, Ibaraki 15-17 May 2016 Introduction We, the Science and Technology Ministers of Canada, France, Germany, Italy, Japan, the United
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationResearch Opportunities & Priorities: WHO/EMRO. Cost Effectiveness Workshop 14 th December, 2014
Research Opportunities & Priorities: WHO/EMRO Cost Effectiveness Workshop 14 th December, 2014 RDI Units Research Promotion & Development (RPD), including Tropical Disease Research (TDR) Innovation & E-Health
More informationBasic social medical insurance in China
Basic social medical insurance in China Ni Yuan,MD Senior lecturer Dalian Medical University Dalian, China BSMI 1 The basic social medical insurance scheme for urban employees Launched by the central government
More informationDifferential Training by Job Function ACRP Job Analysis Results
Differential Training by Job Function ACRP Job Analysis Results Morgean Hirt, ACA, Director of Certification Association of Clinical Research Professionals Disclaimer The views and opinions expressed in
More informationThe EU role in global health
The EU role in global health Contribution of Dominique Kerouedan, MD, MPH, PHD Independent Expert International Health QUESTIONNAIRE: Question 1: In your opinion, does the proposed concept global health
More informationTABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition
TABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition SUMMARY OF SALIENT POINTS Importance and Competitiveness of the Ethical Pharmaceutical Industry Government
More informationSCHISTOSOMIASIS PEDIATRIC PRAZIQUANTEL CONSORTIUM. Treating preschool children
SCHISTOSOMIASIS PEDIATRIC PRAZIQUANTEL CONSORTIUM Treating preschool children PEDIATRIC PRAZIQUANTEL CONSORTIUM Treating preschool children Schistosomiasis is one of the most prevalent parasitic diseases
More informationPlease find below my answers to the questions on The EU role in global health
Jean-Pierre Unger, MD, MPH, PhD Professor of Public Health Institute of Tropical Medicine Antwerp, Belgium jpunger@itg.be Tel 32 3 2476254 Antwerp, November the 18 th, 2009 Dear Sir, Please find below
More informationFSPITS14 - SQA Unit Code H692 04 Negotiate and determine the conditions under which risk will be underwritten in complex insurance cases
Negotiate and determine the conditions under which risk will be Overview This unit is about negotiating and determining the conditions under which complex risk will be underwritten. It therefore includes
More informationA Guide to Clinical Trials
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
More informationEnergizing Innovation. By Kazem Kazempour, PhD, George Steinfels, PhD, MBA and Mukesh Kumar, PhD, RAC
Energizing Innovation By Kazem Kazempour, PhD, George Steinfels, PhD, MBA and Mukesh Kumar, PhD, RAC Former UK Prime Minister Harold Macmillan once said, to be alive at all involves some risk. This statement
More informationLIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by
More informationFrequently Asked Questions (FAQs)
Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing
More informationWits School of Public Health
SHORT COURSES FOR 2016 Wits School of Public Health Division of Epidemiology and Biostatistics Obtain Certificate of Competence in : 1. Processing, Distribution & Archiving I 2. Programming for Research
More informationWHO in 60 years: a chronology of public health milestones
WHO in 60 years: a chronology of public health milestones In 2008, WHO is celebrating its 60 th anniversary. The chronology below tells the story of WHO and public health achievements over the last 60
More informationSECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K. GEOVAX LABS, INC. (Exact name of registrant as specified in its charter)
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
More informationGeneva Association 10th Health and Aging Conference Insuring the Health of an Aging Population
Geneva Association 10th Health and Aging Conference Insuring the Health of an Aging Population November 18, 2013 Diana Dennett EVP, Global Issues and Counsel America s Health Insurance Plans (AHIP) America
More informationIntroduction. VP, Sales in a Global Courier Company
ARTICLE AUGUST 2014 Abstract: Impact analysis of Just in Time packaging and labeling on clinical supply chain Clinical supply chain is in intense pressure for better management due to factors like globalization
More informationScaling up NTD Control: USAID experience. Christy Hanson, PhD, MPH Chief, Infectious Diseases Division
Scaling up NTD Control: USAID experience Christy Hanson, PhD, MPH Chief, Infectious Diseases Division Roadmap to the Neglected Diseases Neglected Diseases HUNDREDS Neglected Tropical Diseases Ascaris Trichuris
More informationIssues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?
ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in
More informationFirst Global Ministerial Conference on Healthy Lifestyles and Noncommunicable Disease Control Moscow, 28-29 April 2011 MOSCOW DECLARATION PREAMBLE
First Global Ministerial Conference on Healthy Lifestyles and Noncommunicable Disease Control Moscow, 28-29 April 2011 MOSCOW DECLARATION PREAMBLE We, the participants in the First Global Ministerial Conference
More informationThe new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
More informationMid-Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au
More informationThe Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
More informationConduct of clinical Trials Communication of
PrinciPles on Conduct of clinical Trials Communication of clinical Trial results Table of Contents Preamble...1 Commitment to Protecting Research Participants...5 Conduct of Clinical Trials...7 Ensuring
More informationRising Health Care Costs What Factors are Driving Increases?
Rising Health Care Costs What Factors are Driving Increases? Rising health care costs and access to affordable coverage are prominent issues for Washington employers, health care providers, purchasers,
More informationIPROVE Innovation Partnership for a Roadmapon VaccinesinEurope
IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope IPROVE IN BRIEF What is IPROVE? Whydo we need IPROVE? IPROVE in actions (How?) Partnership (Who?) WHAT An EU project (FP7) financed by the
More informationEXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice
EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice Battelle is the world s largest non profit independent
More informationSwiss Contributions to Human Resources for Health Development in Low- and Middle- Income Countries
Swiss Contributions to Human Resources for Health Development in Low- and Middle- Income Countries Swiss TPH / SCIH Swiss Contributions to HRH Development in Low- and Middle- Income Countries Editorial
More information2012 Public Policy Priorities A pro-growth, pro-jobs agenda for New York
2012 Public Policy Priorities A pro-growth, pro-jobs agenda for New York 2 Partnership for New York City About the Partnership The Partnership is dedicated to ensuring that New York remains a thriving
More informationPRESCRIPTION MEDICINES: COSTS IN CONTEXT
PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise
More informationFrom: Suerie Moon [redacted] Sent: Friday, November 19, 2010 5:18 PM To: HumanitarianProgram Subject: Comments from the Medicines Patent Pool
From: Suerie Moon [redacted] Sent: Friday, November 19, 2010 5:18 PM To: HumanitarianProgram Subject: Comments from the Medicines Patent Pool Dear Edward and colleagues at USPTO, I am pleased to submit
More informationThe Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder
The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system
More informationCompensation in Safeguarding Children: Pediatric Medical Countermeasure Research
Compensation in Safeguarding Children: Pediatric Medical Countermeasure Research Contents I. Introduction... 1 II. Learning Objectives... 2 III. Background... 2 A. Guiding Ethical Principles... 2 B. Legislative
More informationRegulatory Issues in Genetic Testing and Targeted Drug Development
Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types
More informationPredicting Medication Compliance and Persistency
Predicting Medication Compliance and Persistency By: Jay Bigelow, President Amanda Rhodes, M.P.H., C.H.E.S., Vice President Behavioral Solutions MicroMass Communications, Inc. Introduction A widely recognized
More information